Castro SCJ, Vivas RML

Language: Spanish
References: 12
Page: 111-115
PDF size: 365.92 Kb.

ABSTRACT

Aims: The mixed hyperlipidaenmia requires of combined treatment. Ezetimibe a colesterol absorption inhibitor is an alternative not sufficiently proven in this pathology.
Objetive: Compare the combination of ezetimibe plus bezafibrate against only bezafibrate in patients with mixed hyperlipidaenmia.
Patients and methods: We realised a comparative study type cases and controls. Patients with total colesterol >200 mg/dL and triglycerides between 200 to 500 mg/dL were including. Randomly the patients received bezafibrate 400 mg+ezetimibe 10 mg (bezafibrate+ezetimibe group) and another group only bezafibrate 400 mg. Both groups were followed by a period of 12 weeks. As objective primary we evaluate the percentage of change in the levels of the total colesterol and the triglicerides.
Results: Twenty-four patients in group bezafibrate+ezetimibe and 25 in the bezafibrate group were included. After 12 weeks, the percentage of change in the values of the primary objective was positively majors in the group with double therapy.
Conclusions: The double treatment with bezafibrate + ezetimibe were superior to the treatment with bezafibrate. The combination therapy well was tolerated.

REFERENCES

1. Assmannn G, Schulte H. Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) Study. In: Assmann G, ed. Lipid Metabolism Disorders and Coronary Heart Disease. MMV Medizin Verlag, 1993;pp:21-67.

2. Aguilar-Salinas A, Rojas R, Gómez-Pérez FJ, Valles V, y col. Características de los casos con dislipidemias mixtas en un estudio de población: resultados de la Encuesta Nacional de Enfermedades Crónicas. Salud Publica Mex 2002;44:546- 53.

3. Executive Summary of The Third Report of The National Colesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Colesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

4. Fazio S, Linton MF. The role of fibrates in managing hyperlipidaemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 2004;6:148-57.

5. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002;18:269-76.

6. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17.

7. Farnier M. Ezetimibe in hypercholesterolaemia. Int J Clin Pract 2002;56: 611-14.

8. Knopp RH, Gitter H, Truitt T, Bays H, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41.

9. Kosoglou T, Statkevich P, Fruchart JC, Pember LJC, et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004;20:1197- 207.

10. Farnier M, Freeman MW, Macdonell G, Perevozskaya I, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26:897-905.

11. McKenney JM, Farnier M, Lo KW, Bays HE, et al. Safety and efficacy of long-term co-administration of Fenofibrate and Ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47:1584-7.

12. Knopp RH, Gitter H, Truitt T. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729- 41.